Bayer gets Europe OK for Nexavar in thyroid cancer
Bayer and Amgen unit Onyx Pharmaceuticals Nexava has been granted permission by the European Commission to treat the most common form of thyroid cancer.
Nexavar had already been approved for advanced kidney and liver cancers, has been given the green light for the treatment of metastatic differentiated thyroid carcinoma, that is refractory to radioactive iodine treatment. The approval is based upon data from a trial which showed that the oral multi kinase inhibitor extended progression free survival by 41% compared to placebo.
Joerg Moeller, head of global development at Bayer HealthCare, noted that DTC is a rare but serious disease, “with patients who were lacking new treatment options for over forty years”. The approval marks Nexavar’s third indication in Europe, he noted, “and we are proud to extend this proven treatment option to even more people in need”.
Bayer noted that there are more than 298,000 new cases of thyroid cancer annually and nearly 40,000 people die from the disease worldwide each year. The drug was approved by the FDA for thyroid cancer indication in November of 2013.